Simcere Pharmaceutical Group Ltd
HKEX:2096

Watchlist Manager
Simcere Pharmaceutical Group Ltd Logo
Simcere Pharmaceutical Group Ltd
HKEX:2096
Watchlist
Price: 10.34 HKD Market Closed
Market Cap: 25.7B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Simcere Pharmaceutical Group Ltd

Wall Street analysts forecast Simcere Pharmaceutical Group Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Simcere Pharmaceutical Group Ltd is 9.86 HKD with a low forecast of 7.68 HKD and a high forecast of 11.76 HKD.

Lowest Forecast
Wall Street Target
7.68 HKD
26% Downside
Average Forecast
Wall Street Target
9.86 HKD
5% Downside
Highest Forecast
Wall Street Target
11.76 HKD
14% Upside
Lowest
Price Target
7.68 HKD
26% Downside
Average
Price Target
9.86 HKD
5% Downside
Highest
Price Target
11.76 HKD
14% Upside
Simcere Pharmaceutical Group Ltd Competitors:
Price Targets
4568
Daiichi Sankyo Co Ltd
64% Upside
A
AQST
Aquestive Therapeutics Inc
328% Upside
002653
Haisco Pharmaceutical Group Co Ltd
7% Upside
688185
CanSino Biologics Inc
33% Upside
4568
Daiichi Sankyo Co Ltd
64% Upside
A
AQST
Aquestive Therapeutics Inc
328% Upside
002653
Haisco Pharmaceutical Group Co Ltd
7% Upside
688185
CanSino Biologics Inc
33% Upside
S
4507
Shionogi & Co Ltd
14% Upside
HITI
High Tide Inc
121% Upside
T
1666
Tong Ren Tang Technologies Co Ltd
26% Upside
ACB
Aurora Cannabis Inc
39% Upside

Revenue
Forecast

Revenue Estimate
Simcere Pharmaceutical Group Ltd

For the last 6 years the compound annual growth rate for Simcere Pharmaceutical Group Ltd's revenue is 7%. The projected CAGR for the next 3 years is 15%.

7%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Simcere Pharmaceutical Group Ltd

For the last 6 years the compound annual growth rate for Simcere Pharmaceutical Group Ltd's operating income is 5%. The projected CAGR for the next 3 years is 18%.

5%
Past Growth
18%
Estimated Growth
Estimates Accuracy
9%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Simcere Pharmaceutical Group Ltd

For the last 6 years the compound annual growth rate for Simcere Pharmaceutical Group Ltd's net income is 0%. The projected CAGR for the next 3 years is 30%.

0%
Past Growth
30%
Estimated Growth
Estimates Accuracy
16%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Simcere Pharmaceutical Group Ltd's stock price target?
Price Target
9.86 HKD

According to Wall Street analysts, the average 1-year price target for Simcere Pharmaceutical Group Ltd is 9.86 HKD with a low forecast of 7.68 HKD and a high forecast of 11.76 HKD.

What is Simcere Pharmaceutical Group Ltd's Revenue forecast?
Projected CAGR
15%

For the last 6 years the compound annual growth rate for Simcere Pharmaceutical Group Ltd's revenue is 7%. The projected CAGR for the next 3 years is 15%.

What is Simcere Pharmaceutical Group Ltd's Operating Income forecast?
Projected CAGR
18%

For the last 6 years the compound annual growth rate for Simcere Pharmaceutical Group Ltd's operating income is 5%. The projected CAGR for the next 3 years is 18%.

What is Simcere Pharmaceutical Group Ltd's Net Income forecast?
Projected CAGR
30%

For the last 6 years the compound annual growth rate for Simcere Pharmaceutical Group Ltd's net income is 0%. The projected CAGR for the next 3 years is 30%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.